Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | AZD5312 + Enzalutamide |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
AZD5312 | ISIS-ARRx|ISIS-AZ1Rx|ARRx|AZD-5312 | Antisense Therapy 12 | AZD5312 is an antisense oligonucleotide targeted against androgen receptor (AR), potentially resulting in decreased proliferation and increased apoptosis in AR overexpressing tumors (European Journal of Cancer, Volume 69, S145, PMID: 30462924). | |
Enzalutamide | Xtandi | MDV3100|ASP9785 | Hormone - Anti-androgens 38 | Xtandi (enzalutamide) is a second-generation small molecule androgen receptor (AR) inhibitor that inhibits AR signaling, thereby resulting in decreased tumor growth (PMID: 24009414, PMID: 25945058). Xtandi (enzalutamide) is FDA approved for use in patients with castration-resistant prostate cancer and metastatic hormone-sensitive prostate cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03300505 | Phase Ib/II | AZD5312 + Enzalutamide | ARRx in Combination With Enzalutamide in Metastatic Castration Resistant Prostate Cancer | Suspended | USA | 0 |